<DOC>
	<DOCNO>NCT01459081</DOCNO>
	<brief_summary>The aim study evaluate clinical efficacy safety inhale zanamivir treatment influenza A B virus infection China .</brief_summary>
	<brief_title>Efficacy Safety Inhaled Zanamivir Treatment Influenza A B Virus Infections China</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Encephalitis , Herpes Simplex</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>Who fever ( &gt; 38.0ºC ) At least two follow symptom : chill , headache , myalgia , fatigue , nasal symptom , sore throat , cough Started therapy within 48 hour onset influenzalike illness Written inform consent Respiratory disease , asthma COPD Woman positive urine pregnancy test Woman without contraception study Allergic zanamivir , Paracetamol lactose WBC ≥ 10.5×109/L ; neutrophil percentage ≥ 80 % Hepatic function impairment : AST ≥ 2×ULN , ALT ≥ 2×ULN Renal function impairment : Cr &gt; 221μmol/L Influenza vaccination 12 month prior begin study History tumor , psychiatric disorder , epilepsy drug abuse Patients receive corticosteroid , immunosuppressant HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>